Cj. Destache et al., Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis, J ANTIMICRO, 43, 1999, pp. 107-113
Limited data exist to guide physicians in the cost-effective treatment of a
cute exacerbation of chronic bronchitis (AECB). Therefore, the main objecti
ve of this study was to determine the antimicrobial efficacy and related co
sts for patients with AECB. A retrospective review of 60 outpatient medical
records with a diagnosis of chronic obstructive pulmonary disease (COPD) a
nd chronic bronchitis episodes from a pulmonary clinic of a teaching instit
ution was undertaken. The participating patients had a total of 224 episode
s of AECB requiring antibiotic treatment. Before review, empirical antibiot
ic choices were divided into first-line (amoxycillin, co-trimoxazole, tetra
cyclines, erythromycin), second-line (cephradine, cefuroxime, cefaclor, cef
prozil) and third-line (co-amoxiclav, azithromycin, ciprofloxacin) agents.
Patients receiving first-line agents failed significantly more frequently t
han third-line agents (19% vs 7%, P < 0.05). Additionally, patients prescri
bed first-line agents were hospitalized significantly more often for AECB w
ithin 2 weeks of outpatient treatment as compared with patients prescribed
third-line agents (18.0% vs 5.3% third-line agents; P < 0.02). Time between
subsequent AECB episodes requiring treatment was significantly longer for
patients receiving third-line agents compared with first-line and second-li
ne agents (P < 0.005). Pharmacy costs were lowest with first-line agents (f
irst-line US$10.30 +/- 8.76; second-line US$24.45 +/- 25.65; third-line US$
45.40 +/- 11.11; P < 0.0001), but third-line agents showed a trend towards
lower mean total costs of AECB treatment (first-line US$942 +/- 2173; secon
d-line, US$563 +/- 2296; third-line, US$542 +/- 1946). The use of third-lin
e antimicrobials, co-amoxiclav, ciprofloxacin or azithromycin, significantl
y reduced the failure rate and need for hospitalization, prolonged the time
between AECB episodes, and showed a lower total cost for the management of
AECB. Prospective studies are needed to confirm these findings.